论文部分内容阅读
目的评价干扰素α（ＩＦＮ）的抗肝纤维化作用及其抗病毒疗效的关系。方法干扰素α治疗３６例慢性乙型肝炎患者，对照组用常规方法治疗，治疗前后检测血清肝纤维化指标ＨＡ、ＰＣ－Ⅲ、Ⅳ－Ｃ、ＬＮ以及ＴＧＦ－β１，Ｂ超引导下肝穿作组织学炎症活动度和纤维化程度的评分比较。结果ＩＦＮ组治疗后ＨＡ、ＰＣ－Ⅲ、Ⅳ－Ｃ、ＬＮ和 ＴＧＦ－β１均较治疗前明显降低（Ｐ＜ ０．０１），与对照组治疗后相比较， ＨＡ、 ＰＣ－Ⅲ和 ＴＧＦ－βｌ明显降低（Ｐ＜０．０５）。ＩＦＮ组治疗后组织学炎症活动度评分为（９．３ ± ３．２）分降至（６．２±２．１）分，肝纤维化程度评分由（７．５ ±２．２）分降至（５．１±１．８）分（产值均＜０．０５）。结论肝纤维化程度的改善与毒抗病毒疗效密切相关，α干扰素对慢性乙型肝炎肝纤维化有较好疗效。
Objective To evaluate the anti-hepatic fibrosis effect of interferon α (IFN) and its anti-viral efficacy. Methods Interferon alfa was used to treat 36 patients with chronic hepatitis B. The control group was treated with routine methods. The serum levels of HA, PC-Ⅲ, Ⅳ-C, LN and TGF-β1 were detected before and after treatment. Scores for histological inflammatory activity and fibrosis were compared. Results Compared with the control group, the levels of HA, PC-Ⅲ, Ⅳ-C, LN and TGF-β1 in the IFN group were significantly decreased after treatment (P <0.01) βl decreased significantly (P <0.05). The score of histological inflammatory activity in IFN group was (9.3 ± 3.2) down to (6.2 ± 2.1) and the degree of liver fibrosis was (7.5 ± 2.2) To (5.1 ± 1.8) points (all <0.05). Conclusion The improvement of the degree of liver fibrosis is closely related to the curative effect of poison and anti-virus. Interferon-α is effective in treating chronic hepatitis B with hepatic fibrosis.